Vaccines

Pfizer indicates their RSV vaccine candidate, Abrysvo (RSVpreF), to prevent acute respiratory disease and lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years and older by active immunization.

Two people developed Guillain-Barre syndrome among a total of 19,942 vaccinated participants in the clinical studies submitted for the company’s biologicals license application (BLA).

A booster dose of mRNA COVID-19 vaccination during pregnancy increases protection of infants from infection and related hospitalization.

A new report shows these providers are playing a larger role in vaccine administration, but without federal legislation codifying PREP, half the US states could determine not to continue this path for pharmacists and take away this now vital responsibility.

"We made a mistake," said Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP. "We needed to have a 3-dose primary series and not call these booster shots.”

The candidate, Ad26.RSV.preF–RSV preF protein vaccine, was 80.0% effective against severe disease and 69.8% effective against any RSV acute respiratory infection.

Why have “long COVID” cases become less frequent and less severe over time?

Some chronic hepatitis B patients experienced a dramatic decrease in hepatitis B surface antigen (HBsAg) after receiving a COVID-19 vaccine. Could there be a correlation?

The 2023 changes include vaccines for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.

The vaccine even provided significant protection when children had just one dose, investigators found.

A phase 1 trial with the investigational vaccine, TNX-801, for the prevention of mpox and smallpox is expected to start in the second half of 2023.

New York City has ended their mpox outbreak after months of successful community outreach and vaccination campaigns.

This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.

The designation was based on positive top line data from the ConquerRSV phase 3 efficacy trial.

In the latest Morbidity and Mortality Weekly Report, authors offer some strategies to avoid SARS-CoV-2 infection in this patient population as well as the US government changes course on COVID-19 vaccine policy.

The week's most-clicked COVID-19 stories included vaccine updates, new variants, and a pivotal FDA advisory committee vote.

Novavax will update its protein-based COVID-19 vaccine, but maintains the current vaccine is effective against current and future variants.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to move toward a unified strain composition for COVID-19 primary and booster vaccines.

In the CDC’s latest Morbidity and Mortality Weekly Report, investigators reported the Moderna and Pfizer-BioNTech updated vaccines helped prevent acute infection from the latest Omicron mutations.

The Pfizer-BioNTech COVID-19 vaccine was associated with rare instances of myo/pericarditis and acute kidney injury, according to a nationwide study in New Zealand that confirmed the safety profile of the vaccine.

A recreation of a failed staph vaccine trial unveiled that previous exposure to S aureus made the vaccine candidate ineffective.

Rapidly distributing vaccines to at least 1/3 of at-risk populations, in addition to increasing tasting and contact tracing, may adequately stop the spread of mpox.

Reported reasons adults had not received a bivalent COVID-19 booster dose differed across age groups.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

Although vaccine rates overall remain high, a new report shows a reduction 2 years in a row, leaving thousands of children not vaccinated against vaccine-preventable viruses.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

This act designed to allow pharmacists and technicians the ability to administer certain vaccines without a prescriber order will lapse next year. A new report looks at vaccination trends in the US and how pharmacists are playing a vital role in administering vaccines.

With these results, the company plans to submit their investigational vaccine, MRNA-1345, for regulatory approval in the first half of 2023.

Preclinical testing suggests that a newly developed SARS-CoV-2 vaccine could protect against current and future variants.

The agency licensed the new indication for Sanofi’s Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) shot for immunization during the third trimester of pregnancy.